Ling Dai

491 total citations
28 papers, 347 citations indexed

About

Ling Dai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ling Dai has authored 28 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Ling Dai's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ling Dai is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Ling Dai collaborates with scholars based in China, Ethiopia and United States. Ling Dai's co-authors include Jun Nie, Xiangjuan Ma, Weiheng Hu, Guangming Tian, Jindi Han, Di Wu, Xiaoling Chen, Sen Han, Jian Fang and Jie Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Cancer.

In The Last Decade

Ling Dai

25 papers receiving 342 citations

Peers

Countries citing papers authored by Ling Dai

Since Specialization

Citations

This map shows the geographic impact of Ling Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Dai more than expected).

Fields of papers citing papers by Ling Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Dai. The network helps show where Ling Dai may publish in the future.

Co-authorship network of co-authors of Ling Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Dai. A scholar is included among the top collaborators of Ling Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Dai. Ling Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune checkpoint inhibitor-related myocarditis in patients with lung cancer 2025 ·BMC Cancer ·Wenli Cao, Sen Han, (unknown), Lan Mi, Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Di Wu, (unknown), Ziran Zhang, (unknown), Jian Fang, (unknown)	3
2	Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China 2025 ·Frontiers in Oncology ·Guangming Tian, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiangjuan Ma, Xiaoling Chen, Sen Han, Jindi Han, Ziran Zhang, (unknown), Xinliang Zhao, (unknown)	0
3	Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer 2024 ·Heliyon ·(unknown), (unknown), Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Sen Han, (unknown), Yang Wang, Ziran Zhang, (unknown), Jian Fang	6
4	Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis 2023 ·BMC Pulmonary Medicine ·Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Sen Han, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Ziran Zhang, (unknown), Jian Fang	5
5	Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer 2023 ·Frontiers in Oncology ·Jie Zhang, (unknown), Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang	5
6	The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies 2022 ·Journal of Thoracic Disease ·Guangming Tian, Xinliang Zhao, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, (unknown), Jindi Han, Xiangjuan Ma, Di Wu, Sen Han, (unknown), Yang Wang, Ziran Zhang, Jian Fang	1
7	Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study 2022 ·Cancer Medicine ·Yang Wang, Xuanye Zhang, (unknown), Sen Han, Jie Zhang, Jun Nie, Ling Dai, Weiheng Hu, (unknown), Xiangjuan Ma, Guangming Tian, Di Wu, Ziran Zhang, (unknown), Jian Fang	1
8	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC 2021 ·Cancer Immunology Immunotherapy ·Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Di Wu, (unknown), Ziran Zhang, (unknown)	4
9	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China 2021 ·Frontiers in Oncology ·Xiaoling Chen, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Di Wu, Yang Wang, (unknown), Ziran Zhang, (unknown)	28
10	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study 2021 ·Technology in Cancer Research & Treatment ·Jie Zhang, Di Wu, Ziran Zhang, (unknown), Guangming Tian, Yang Wang, Xiangjuan Ma, (unknown), Jindi Han, Weiheng Hu, Ling Dai, Jun Nie, Jian Fang	3
11	High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer 2018 ·Cancer Management and Research ·Ling Dai, Guangdong Pan, Xiaojia Liu, Jiang Huang, (unknown), (unknown), (unknown), Qing Xu, Ning Tan	38
12	Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma 2018 ·Thoracic Cancer ·Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, (unknown), Ziran Zhang, Jian Fang	7
13	Upregulation of caprin1 expression is associated with poor prognosis in hepatocellular carcinoma 2017 ·Pathology - Research and Practice ·Ning Tan, Ling Dai, Xiaojia Liu, Guangdong Pan, Hui Chen, Jiang Huang, Qing Xu	21
14	Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma. 2017 ·Journal of Clinical Oncology ·Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Jindi Han, Sen Han, Yang Wang, (unknown)	0
15	Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer 2016 ·Medicine ·Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Jie Zhang, (unknown), Xiangjuan Ma, Guangming Tian, Di Wu, Sen Han, Jindi Han, (unknown), (unknown)	11
16	[Effects of Local Radiation Combined with Chemotherapy in the treatment of  Patients with Extensive-stage Small Cell Lung Cancer]. 2015 ·SHILAP Revista de lepidopterología ·Di Wu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Weiheng Hu, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, (unknown), Yang Wang	2
17	Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer. 2015 ·Journal of Clinical Oncology ·Jie Zhang, Jian Fang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Di Wu	0
18	Circulating PD‐L1 in NSCLC patients and the correlation between the level of PD‐L1 expression and the clinical characteristics 2015 ·Thoracic Cancer ·Jie Zhang, Jing Gao, Yanyan Li, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Di Wu, Lin Shen, Jian Fang	109
19	Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer 2014 ·Thoracic Cancer ·Jie Zhang, Shaolei Li, (unknown), Jindi Han, Jun Nie, Ling Dai, Weiheng Hu, Guangming Tian, Xiangjuan Ma, Sen Han, Di Wu, Qingfeng Zheng, Yue Yang, Jian Fang	10
20	Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails 2014 ·Cancer Chemotherapy and Pharmacology ·Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, (unknown), Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact